Arcutis Launches ZORYVE (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

10.08.2022 - Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated steroid-free cream that rapidly clear plaques and reduces itch Arcutis committed ... Seite 1

Related Keywords

United States , ,Hydroarq Technology ,Arcutis Biotherapeutics Inc ,Nasdaq ,Arcutis Cares ,Ken Lock ,Chief Commercial Officer ,